SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentari...
November 25 2014 - 6:15PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the District
of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc.
(“Aeterna Zentaris” or the “Company”) (Nasdaq: AEZS) securities
during the period between October 18, 2012 and November 6, 2014,
inclusive (the “Class Period”). Investors who wish to become
proactively involved in the litigation have until January 12, 2015
to seek appointment as lead plaintiff.
If you have suffered a loss from investment in Aeterna Zentaris
securities purchased on or after October 18, 2012 and held through
the revelation of negative information during and/or at the end of
the Class Period, as described below, and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at: http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. No class has yet been certified in the above action.
Members of the Class will be represented by the lead plaintiff and
counsel chosen by the lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement and how much of a settlement to accept for the Class in
the action. The lead plaintiff will be selected from among
applicants claiming the largest loss from investment in Company
units during the Class Period. Brower Piven also encourages anyone
with information regarding the Company’s conduct during the period
in question to contact the firm, including whistleblowers, former
employees, shareholders and others.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of their failure to
disclose during the Class Period that because certain patients –
those with confirmed growth hormone deficiency – were included in
the results of the Company’s Phase III clinical trial for its drug
MACRILEN(TM), the results failed to meet the objectives of the
Special Protocol Assessment agreed to with the FDA. According to
the complaint, following the Company’s November 6, 2014
announcement that it had received a Complete Response Letter
indicating the FDA would not approve the Company’s MACRILEN NDA and
required a new confirmatory clinical trial to demonstrate the
efficacy of MACRILEN as a diagnostic test for growth
hormone, the value of Aeterna Zentaris shares declined
significantly.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024